EyePoint Pharmaceuticals Inc(EYPT) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. The company provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery; and Retisert, a sustained-release implant for the treatment of posterior segment uveitis. It is also developing EYP-1901, a 6-month bioerodible Durasert Vorolanib tyrosine kinase inhibitor, for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. The company also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Current Price

$9.08

RSI

21.267

Beta:

1.3475

March 31, 2021
42.7M
5.7M

-35.743 %
63.453 %
-48.598 %
10.540 %

$26,275,000
$10,379,000
$2,928,000
$-24,037,000
$7,539,000
$1,620,000
153.155 %
254.474 %
112.181 %
-418.835 %
365.370 %

$-45,394,000
$-56,793,000
$-44,720,000
$-53,171,000
$-18,485,000
$-21,702,000
20.071 %
-26.997 %
15.894 %
-187.644 %
14.824 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.